Third-line therapy for chronic myeloid leukemia: current status and future directions

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optim...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research